Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer

ClinicalTrials.gov ID

NCT07707674

Lead Sponsor

Evopoint Biosciences Inc.INDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 1

Enrollment

24Estimated

Last Update Posted

Jul 22, 2026Actual

Start Date

Jul 30, 2026Estimated

Primary Completion Date

Apr 30, 2028Estimated

Completion Date

Apr 30, 2028Estimated

Official Title

A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects With Metastatic Pancreatic Cancer

Brief Summary

A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects with Metastatic Pancreatic Cancer

• Metastatic Pancreatic Cancer

• XNW28012

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. subjects with histologically or cytologically confirmed metastatic PDAC, whose disease has progressed after at least 1 prior systemic therapy.

2. Age ≥ 18 years old at the time of consent.

3. Subjects must have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale. ECOG status of 2 can be allowed if it is a result of disease progression and warrantsdiscussion with the medical monitor.

4. Subjects must have adequate organ function within 7 days prior to the first study drug administration, as indicated by the following laboratory values;

5. Life expectancy of at least 12 weeks.

6. Females of childbearing potential must have a negative pregnancy test within 7 days prior to the first dose of study drug.

7. Non-sterile subjects must be willing to use a highly effective contraception (e.g., IUD, pill, or condom) for the duration of the study and for 6 months after the last dose of study drug unless their partner is sterilized.

8. Subjects are able to provide written informed consent, understand and are willing to comply with the requirements of the study.

   -

Exclusion Criteria:

1. A history of severe infusion reactions to other monoclonal antibodies/antibody drug conjugates (ADCs), or allergic reactions to any components of XNW28012, or treatment with TF-directed therapy.
2. Any anti-tumor therapy within 21 days prior to the first dose, including but not limited to: small molecules, immunotherapy, chemotherapy, monoclonal antibodies, or any other experimental drugs.
3. Any active malignancy, with the exception of the specific types of cancersunder investigation in this study and any locally recurring cancer that has been treated curatively .
4. Have received a live vaccine within 4 weeks prior to the first dose of study drug. Note: Seasonal vaccines for influenza are generally inactivated vaccines and are allowed; however, intranasal influenza vaccines will not be allowed if they are attenuated live vaccines.
5. Have received granulocyte colony stimulating factor (G-CSF) or granulocyte / macrophage colony stimulating factor support within 1 week before screening, or pegylated G-CSF within 2 weeks before screening.
6. Subjects with toxicities (as a result of prior anti-cancer therapy) that have not improved to CTCAE grade ≤ 1 or stabilized, except those AEs not considered as a likely safety risk (e.g., alopecia).
7. Any history of pneumonitis or interstitial lung disease (ILD).
8. Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke (transient ischemic attack) ≤ 3 months prior to screening is allowed if stable.
9. Any hematological risk factors.
10. Clinically significant cardiovascular/cerebrovascular conditions.
11. Subjects have known active CNS metastases and/or carcinomatous meningitis.
12. Active ocular surface disease at screening, or subjects with any prior episode of cicatricial conjunctivitis, or corneal nebula; subjects with glaucoma of CTCAE grade ≥ 2.
13. Any history of Toxic Epidermal Necrolysis (TEN) or Steven Johnson Syndrome.
14. Subjects who have undergone major surgery within 28 days prior to the first dose of study drug, except if the procedure is minimally invasive.
15. Subjects with untreated chronic hepatitis B or chronic hepatitis B virus (HBV) carriers whose HBV DNA is higher than 500 IU/mL or subjects with positive hepatitis C virus (HCV) RNA. Inactive hepatitis B surface antigen (HbsAg) carriers, treated and stable hepatitis B (HBV DNA < 500 IU/mL), and cured hepatitis C subjects may be enrolled.
16. A known history of HIV infection or acquired immunodeficiency syndrome (AIDS).
17. Subjects with severe chronic or active infections requiring antibacterial, antifungal or antiviral therapy.
18. Known immunodeficiency or any condition that requires systemic treatment with either corticosteroids (≥ 10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days before the first dose of study drug.
19. Subjects who have received (or plan to receive during the study treatment period) strong/moderate CYP3A4 inhibitors or inducers, or strong/moderate CYP2D6 inhibitors within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of study drug.
20. Have an ongoing significant, uncontrolled medical condition.
21. Subjects who are pregnant or breastfeeding or expecting to conceive within the projected duration of the study.
22. Underlying medical conditions or alcohol, drug abuse or dependence that, in Investigator's opinion, will be unfavorable for the administration of study drug or affect the explanation of drug toxicity or adverse events, or insufficient compliance during the study according to Investigator's judgment.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Evopoint Biosciences Inc.INDUSTRY

hopeteam@startresearch.com+1 (616) 954-5554

hopeteam@startresearch.com+1 (363) 207-5160

CancerAnswer@ccf.org+1 (216) 444-7923

SCC-Clinical-Trials-Office@ouhsc.edu+1 (405) 271-1112

scri.referrals@scri.com+1 (615) 329-7640

reva.schneider@scri.com+1 (972) 566-3000

hopeteam@startresearch.com+1 (210) 593-5250

• Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

  NCT06799637

  RecruitingInterventionalPhase 1Phase 2Updated Apr 15, 2026
• A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor

  NCT07327294

  Not yet recruitingInterventionalPhase 1Phase 2Updated Jan 8, 2026
• Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors

  NCT03901950

  CompletedInterventionalPhase 1Updated Feb 16, 2023
• To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors

  NCT06558513

  CompletedInterventionalPhase 1Phase 2Updated Jan 12, 2026
• XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

  NCT06792435

  Active, not recruitingInterventionalPhase 1Phase 2Updated Aug 11, 2026
• A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment

  NCT06987500

  RecruitingInterventionalPhase 1Phase 2Updated Jun 6, 2025